Health ❯Cardiovascular Health
Clinical Trials Biotechnology Preventive Medicine Cholesterol Management Adverse Events Stock Market Genetic Engineering FDA Approvals Research and Development Clinical Research
The therapy achieved up to 53% LDL cholesterol reduction without serious side effects, advancing toward Phase 2 trials in late 2025.
